


# Rhodium-Catalyzed Asymmetric Conjugate Additions of Boronic Acids to Enones Using DIPHONANE: A Novel Chiral Bisphosphine Ligand

Koen Vandyck, Bavo Matthys, Mario Willen, Koen Robeyns,<sup>†</sup>  
Luc Van Meervelt,<sup>†</sup> and Johan Van der Eycken\*

Laboratory for Organic and Bioorganic Synthesis, Department of Organic Chemistry,  
Ghent University, Krijgslaan 281 (S.4), B-9000 Gent, Belgium  
johan.vandereycken@ugent.be

Received September 20, 2005 (Revised Manuscript Received December 6, 2005)

## ABSTRACT



The synthesis of a novel enantiopure *C*<sub>2</sub>-symmetric bisphosphine, DIPHONANE, was accomplished starting from 2,5-norbornadione, utilizing (*R,R*)- and/or (*S,S*)-(2,3-*O*-di[(phenylamino)carbonyl]tartaric acid for the resolution of an intermediate phosphineoxide. The application of this ligand in the rhodium-catalyzed asymmetric conjugate addition of boronic acids to cyclic enones provides the 1,4-addition products in good yields (69–98%) and high ee's (78–95% ee). A byproduct arising from a consecutive 1,4-addition and 1,2-addition was also observed.

The 1,4-addition of aryl or alkenyl groups to electron-deficient double bonds constitutes an interesting approach for C–C bond formation.<sup>1</sup> Therefore, the asymmetric rhodium-catalyzed 1,4-addition to  $\alpha,\beta$ -unsaturated enones has recently received a lot of attention applying various ligands such as biaryl bisphosphines,<sup>2</sup> phosphoramidites,<sup>3a,b</sup> BINOL-based diphosphonites,<sup>3c</sup> amidomonophosphines,<sup>3d</sup> N-heterocyclic carbenes,<sup>3e</sup> ferrocenyl-based bisphosphines,<sup>2c</sup> a P-chiral

phosphine,<sup>3f</sup> and dienes.<sup>3g–k</sup> Some other bisphosphine ligands, although efficient in the Rh(I)-catalyzed hydrogenation, fail


<sup>†</sup> Biomolecular Architecture, Department of Chemistry, K. U. Leuven, Celestijnenlaan 200F, B-3001 Leuven (Heverlee), Belgium.

(1) For a review on rhodium-catalyzed asymmetric 1,4-addition and C–C bond formation, respectively, see: (a) Hayashi, T.; Yamasaki, K. *Chem. Rev.* **2003**, *103*, 2829–2844. (b) Fagnou, K.; Lautens, M. *Chem. Rev.* **2003**, *103*, 169–196.

(2) (a) Takaya, Y.; Ogasawara, M.; Hayashi, T.; Sakai, M.; Miyaura, N. *J. Am. Chem. Soc.* **1998**, *120*, 5579–5580. (b) Amengual, R.; Michelet, V.; Genêt, J.-P. *Synlett* **2002**, 1791–1794. (c) Pucheault, M.; Darses, S.; Genêt, J.-P. *Eur. J. Org. Chem.* **2002**, 3552–3557. (d) Shi, Q.; Xu, L.; Li, X.; Jia, X.; Wang, R.; Au-Yeung, T. T.-L.; Chan, A. S. C.; Hayashi, T.; Cao, R.; Hong, M. *Tetrahedron Lett.* **2003**, *44*, 6505–6508. (e) Madec, J.; Michaud, G.; Genêt, J.-P.; Marinetti, A. *Tetrahedron: Asymmetry* **2004**, *15*, 2253–2261. (f) Yuan, W.-Y.; Cun, L.-F.; Gong, L.-Z.; Mi, A.-Q.; Jiang, Y.-Z. *Tetrahedron Lett.* **2005**, *46*, 509–512. (g) Ogasawara, M.; Ngo, H. L.; Sakamoto, T.; Takahashi, T.; Lin, W. *Org. Lett.* **2005**, *7*, 2881–2884.

(3) (a) Boiteau, J.-G.; Minnaard, A. J.; Feringa, B. L. *J. Org. Chem.* **2003**, *68*, 9481–9484. (b) Iguchi, Y.; Itooka, R.; Miyaura, N. *Synlett* **2003**, 1040–1042. (c) Reetz, M. T.; Moulin, D.; Gosberg, A. *Org. Lett.* **2001**, *3*, 4083–4085. (d) Kuriyama, M.; Nagai, K.; Yamada, K.-I.; Miwa, Y.; Taga, T.; Tomioka, K. *J. Am. Chem. Soc.* **2002**, *124*, 8932–8939. (e) Ma, Y.; Song, S.; Ma, C.; Sun, Z.; Chai, Q.; Andrus, M. B. *Angew. Chem., Int. Ed.* **2003**, *42*, 5871–5874. (f) Imamoto, T.; Sugita, K.; Yoshida, K. *J. Am. Chem. Soc.* **2005**, *127*, 11934–11935. (g) Defieber, C.; Paquin, J.-F.; Serna, S.; Carreira, E. M. *Org. Lett.* **2004**, *6*, 3873–3876. (h) Hayashi, T.; Ueyama, K.; Tokunaga, N.; Yoshida, K. *J. Am. Chem. Soc.* **2003**, *125*, 11508–11509. (i) Otomaru, Y.; Kina, A.; Shintani, R.; Hayashi, T. *Tetrahedron: Asymmetry* **2005**, *16*, 1673–1679. (j) Otomaru, Y.; Okamoto, K.; Shintani, R.; Hayashi, T. *J. Org. Chem.* **2005**, *70*, 2503–2508. (k) Lang, F.; Breher, F.; Stein, D.; Grützmacher, H. *Organometallics* **2005**, *24*, 2997–3007. For some recent results on 1,4-additions to other  $\alpha,\beta$ -unsaturated systems, see: (l) Paquin, J. F.; Defieber, C.; Stephenson, C. R. J.; Carreira, E. M. *J. Am. Chem. Soc.* **2005**, *127*, 10850–10851 for enals. (m) Paquin, J. F.; Stephenson, C. R. J.; Defieber, C.; Carreira, E. M. *Org. Lett.* **2005**, *7*, 3821–3824 for acrylic esters. (n) Shintani, R.; Duan, W. L.; Nagano, T.; Okada, A.; Hayashi, T. *Angew. Chem., Int. Ed.* **2005**, *44*, 4611–4614 for maleimides. (o) Shintani, R.; Kimura, T.; Hayashi, T. *Chem. Commun.* **2005**, 25, 3213–3214 for Weinreb amides. (p) Jagt, R. B. C.; de Vries, J. G.; Feringa, B. L.; Minnaard, A. J. *Org. Lett.* **2005**, *7*, 2433–2435 for 2,3-dihydro-4-pyridones. (q) Chen, G.; Tokunaga, N.; Hayashi, T. *Org. Lett.* **2005**, *7*, 2285–2288 and references therein for coumarins.


to induce high reactivity and/or selectivity in the rhodium-catalyzed 1,4-addition to  $\alpha,\beta$ -unsaturated enones.<sup>1,2a,c</sup> Within our interest for the design of new ligand architectures<sup>4</sup> and stimulated by the synthesis of DIANANE<sup>5</sup> (Figure 1), we



**Figure 1.**

wish to present our results concerning the synthesis and application of a novel  $C_2$ -symmetric bisphosphine, DIPHONANE.


Our approach started with the known 2,5-norbornadione ( $\pm$ )-**1**<sup>6</sup> (Scheme 1). Dienolization/alkylation of this interme-



diate is usually addressed in two separate steps,<sup>3h,j,7</sup> but nevertheless the dienolization with KHMDS followed by treatment with PhNTf<sub>2</sub> gave a satisfactory yield of the bistriflate ( $\pm$ )-**2**. Pd(0)-catalyzed coupling of **2** with HPPH<sub>2</sub> and subsequent oxidation resulted in the racemic vinylic bisphosphineoxide ( $\pm$ )-**3**.<sup>8,9</sup> This intermediate was preferred over its phosphino-borane complex because it allows resolu-

tion by applying the hydrogen bonding capacity of the phosphineoxide and BH<sub>3</sub>-protected phosphines tend to act as a catalyst poison for heterogeneous hydrogenation.<sup>10</sup> Hydrogenation with Pd on charcoal (10 w/w %) resulted stereoselectively in *endo*-bisphosphine-oxide ( $\pm$ )-**4**.

The bis-*endo* configuration of ( $\pm$ )-**4** could be deduced from the <sup>3</sup>J<sub>PC</sub> coupling in the <sup>31</sup>P NMR spectrum of P with C<sub>7</sub> being 15.2 Hz (expected *endo* = 12–16.8 Hz, *exo*  $\approx$  0 Hz).<sup>11</sup> Nevertheless, resolutions applying commercial (*R,R*)-(-)-di-*O,O*-benzoyltartaric acid (DBTA) **7**, *R*-(-)-mandelic acid **9**, or (1*R*)-(-)-camphorsulfonic acid (CSA) **10** (Figure 2) were unsuccessful. Fortunately, when (*R,R*)-(2,3-di-



**Figure 2.** Chiral acids tested for the resolution of ( $\pm$ )-**4**.

[(phenylamino)carbonyl]tartaric acid **8** or its enantiomer was applied (both obtained in three steps from the corresponding tartaric acid<sup>12</sup>), bis-phosphineoxide ( $\pm$ )-**4** was resolved with high enantiomeric excess (>98% ee), as determined by HPLC analysis with a chiral stationary phase column (Chiralpak AD-H). In this way, enantiomerically pure (2*S*,5*S*)-**4** could be obtained in 35% yield in two steps from ( $\pm$ )-**3**. Reduction of the phosphineoxide (HSi(OEt)<sub>3</sub>, Ti(OiPr)<sub>4</sub>)<sup>13</sup> was followed by reprotection with BH<sub>3</sub> to ensure easy purification of the phosphine precursor, resulting in the isolation of **5**. Again, the <sup>3</sup>J<sub>PC</sub> coupling with C<sub>7</sub> appeared to be large (12.8 Hz), proving that no epimerization had occurred. The absolute configuration of **5**, being (+)-(1*S*,2*S*,4*S*,5*S*) was established by single-crystal X-ray diffraction (Figure 3).<sup>8</sup> By refluxing the phosphine-borane in EtOH, an efficient procedure recently applied in our group for mild deprotection of phosphines,<sup>14</sup> DIPHONANE **6** was obtained.

The efficiency of our new ligand was tested in the rhodium-catalyzed 1,4-addition of arylboronic acids to enones (Table 1).<sup>1–3</sup> We first examined the addition of phenylboronic acid **12a** to cyclohexenone **11A**. In accordance

(4) (a) Vandyck, K.; Matthys, B.; Van der Eycken, J. *Tetrahedron. Lett.* **2005**, 46, 75–78. (b) Kuppens T.; Vandyck K.; Van der Eycken J.; Herrebout W.; van der Veken, B. J.; Bultinck P. *J. Org. Chem.* **2005**, 70, 9103–9114. (c) De Coster, G.; Vandyck, K.; Van der Eycken, E.; Van der Eycken, J.; Elseviers, M.; Röper, H. *Tetrahedron: Asymmetry* **2002**, 13, 1673–1679.

(5) (a) Berkessel, A.; Schröder, M.; Sklorz, C. A.; Tabanella, S.; Vogl, N.; Lex, J.; Neudörfl, J. M. *J. Org. Chem.* **2004**, 69, 3050–3056. (b) Berkessel, A.; Menche, D.; Sklorz, C. A.; Schröder, M.; Paterson I. *Angew. Chem., Int. Ed.* **2003**, 42, 1032–1035.

(6) Hawkins, R. T.; Hsu, R. S.; Wood, S. G. *J. Org. Chem.* **1978**, 43, 4648–4650.

(7) Smith, B. T.; Wendt, J. A.; Aube, J. *Org. Lett.* **2002**, 4, 2577–2579.

(8) See Supporting Information for X-ray diffraction structure.

(9) Gilbertson, S. R.; Fu, Z.; Starkey, G. W. *Tetrahedron Lett.* **1999**, 40, 8509–8512.


(10) (a) Boerner, A.; Ward, J.; Ruth, W.; Holz, J.; Kless, A.; Heller, D.; Kagan, H. B. *Tetrahedron* **1994**, 50, 10419–10430. (b) Vandyck, K.; Van der Eycken, J. Unpublished results.

(11) Maffei, M.; Buono, G. *New J. Chem.* **1988**, 12, 923–930.

(12) (a) Cereghetti, M.; Rageot, A. European Patent 511 558, 1992. (b) Cereghetti, M.; Schmid, R.; Schönholzer, P.; Rageot, A. *Tetrahedron Lett.* **1996**, 37, 5343–5346. (c) Chen, Y.-X.; Li, Y.-M.; Lam, K.-H.; Chan, A. S. C. *Chin. J. Chem.* **2001**, 19, 794–799.

(13) Coumbe, T.; Lawrence, J. N.; Muhammad, F. *Tetrahedron Lett.* **1994**, 35, 625–628.

(14) Although addition of DABCO accelerated the reaction, it was not crucial to obtain full conversion. For deprotection with EtOH, see: (a) Moulin, D.; Bago, S.; Bauduin, C.; Darcel, C.; Jugé, S. *Tetrahedron: Asymmetry* **2000**, 11, 3939–3956. (b) Vervecken, E.; Van der Eycken, J. To be submitted.



**Figure 3.** X-ray crystal structure of (2*S*,5*S*)-5.

with earlier findings,<sup>15</sup> we observed that the generation of the catalyst from  $[\text{RhCl}(\text{C}_2\text{H}_4)_2]_2$  in the presence of KOH and (*S,S*)-DIPHONANE (entry 1) resulted in a more active catalyst than in the case of (*S,S*)-DIPHONANE with  $\text{Rh}(\text{acac})(\text{C}_2\text{H}_4)_2$  (entries 2 and 3), whereas the 1,4-addition product was produced with comparable enantiomeric excess (85% and 86% ee, respectively). The use of 3 mol % of catalyst (entry 4) instead of 1 mol % (entry 1) resulted in an equal enantiomeric excess (85%). The  $[\text{RhCl}(\text{C}_2\text{H}_4)_2]_2/\text{KOH}/\text{DIPHONANE}$  system allowed lowering the reaction tem-

**Table 1.** Asymmetric 1,4-Addition of Phenylboronic Acid **12a** to Cyclohexenone **11A**<sup>a</sup>

entry	temp (°C)	solvent	time (h)	<b>13Aa</b> (%) <sup>b</sup>	ee (%) <sup>c</sup>	<b>14Aa</b> [%] <sup>d</sup>
1	100	dioxane/H <sub>2</sub> O 10/1	2	66	85	5
2 <sup>e</sup>	100	dioxane/H <sub>2</sub> O 10/1	5	43	86	1
3 <sup>e</sup>	80	dioxane/H <sub>2</sub> O 10/1	21	50	87	1
4 <sup>f</sup>	100	dioxane/H <sub>2</sub> O 10/1	3	72	85	7
5	60	dioxane/H <sub>2</sub> O 10/1	4	83	90	6 (88)
6	50	dioxane/H <sub>2</sub> O 10/1	4	78	91	12 (89)
7 <sup>g</sup>	50	dioxane/H <sub>2</sub> O 10/1	16	65	87	<1
8	50	DME/H <sub>2</sub> O 10/1	16	69	90	<1
9	50	EtOH/H <sub>2</sub> O 10/1	16	76	91	4
10	50	toluene/H <sub>2</sub> O 10/1	21	9	nd	<1
11	50	dioxane/H <sub>2</sub> O 5/1	4	63	90	3
12	50	ethyleneglycol/ dioxane 3/1	6	67	89	6
13	50	2-ethoxyethanol	21	74	90	10
14 <sup>h</sup>	45	dioxane/H <sub>2</sub> O 10/1	19	50	91	32 (89) <sup>i</sup>

<sup>a</sup> Standard conditions  $[\text{RhCl}(\text{C}_2\text{H}_4)_2]_2/\text{DIPHONANE}/\text{cyclohexenone}$  0.5/1.1/100, ~0.35 M **11A**, 1.5 equiv KOH, 5 equiv  $\text{PhB}(\text{OH})_2$ . <sup>b</sup> Isolated as a mixture with **14Aa**. <sup>c</sup> Determined by HPLC analysis with a chiral stationary phase column (Chiralcel AD-H). <sup>d</sup> Determined from <sup>1</sup>H NMR ratio with (*R*)-**13Aa** based on **11A**, enantiomeric excess determined by HPLC analysis with a chiral stationary phase column (Chiralcel OD-H). <sup>e</sup> 1%  $\text{Rh}(\text{acac})(\text{C}_2\text{H}_4)_2$  was used as catalyst precursor without the addition of base. <sup>f</sup> 1.5%  $[\text{RhCl}(\text{C}_2\text{H}_4)_2]_2$  was used. <sup>g</sup> 1.5 equiv  $\text{NEt}_3$  was applied as a base. <sup>h</sup> 0.91 M **11A**, 2 equiv  $\text{PhB}(\text{OH})_2$ . <sup>i</sup> ~95% de.

perature to 50 °C (entries 5 and 6), affording the product with an enantiomeric excess of 91%. Changing the base from KOH to  $\text{NEt}_3$  (entry 7) or changing the solvent (entries 8–13) did not lead to better results.

As a byproduct, resulting from the asymmetric 1,4-addition and a consecutive 1,2-addition, (1*R*,3*R*)-1,3-diphenyl-cyclohexanol **14Aa** could be isolated.<sup>16</sup> The Rh(I)-catalyzed 1,2-arylation of ketones is usually limited to strained ketones as acceptor or to intramolecular additions, whereas arylation of aldehydes or aldimines has been described to a much larger extent.<sup>1,17</sup> The 1,2-addition showed a high level of diastereoselectivity (95% de, entry 14), whereas the resulting product **14Aa** showed a comparable enantiomeric excess as the initial 1,4-adduct **13Aa** (entries 5, 6, and 14). At higher concentration (0.91 M **11A**) **14Aa** was formed in up to 32%, applying only 2 equiv **12a** at 45 °C.

Extending the Rh(I)/DIPHONANE-catalyzed addition to a variety of boronic acids **12a–f** and a range of acceptors **11A–E** (Table 2) revealed high selectivity in the addition of 4- $\text{CF}_3$ -Ph (**12b**) and 1-naphthyl boronic acid (**12d**) to cyclohexenone (**11A**, 92% ee, entry 1, and 95% ee, entry 3, respectively). The hindered *o*-tolyl boronic acid (**12e**) gave

**Table 2.** Asymmetric 1,4-Addition of Arylboronic Acids **12a–f** to  $\alpha,\beta$ -Unsaturated Enones **11A–E**

entry	<b>11</b>	<b>12</b>	time (h)	yield (%) <sup>a</sup> of <b>13</b>	ee [%] <sup>b</sup> (config)
1	<b>11A</b>	<b>12b</b>	19	78 ( <b>13Ab</b> )	92 ( <i>R</i> )
2	<b>11A</b>	<b>12c</b>	4	73 ( <b>13Ac</b> )	79 ( <i>R</i> )
3	<b>11A</b>	<b>12d</b>	4	95 ( <b>13Ad</b> )	95 ( <i>R</i> )
4	<b>11A</b>	<b>12e</b>	20	69 ( <b>13Ae</b> )	78 ( <i>R</i> )
5	<b>11A</b>	<b>12f</b>	20	nc ( <b>13Af</b> )	
6	<b>11B</b>	<b>12a</b>	4	96 ( <b>13Ba</b> )	83 ( <i>R</i> )
7	<b>11C</b>	<b>12a</b>	4	98 ( <b>13Ca</b> )	86 ( <i>R</i> )
8	<b>11C</b>	<b>12d</b>	4	96 ( <b>13Cd</b> )	95 (+)
9 <sup>c</sup>	<b>11D</b>	<b>12a</b>	17	nc ( <b>13Da</b> )	
10	<b>11E</b>	<b>12a</b>	19	96 ( <b>13Ea</b> )	31 ( <i>S</i> )

<sup>a</sup> Isolated yield. nc = no conversion. <sup>b</sup> Determined by HPLC analysis with a chiral stationary phase column (Chiralpak AD-H or Chiralcel OD-H). <sup>c</sup> 3%  $\text{Rh}(\text{acac})(\text{CH}_2\text{CH}_2)_2$ , 3.3% (*S,S*)-**6**, dioxane/H<sub>2</sub>O 10/1, 100 °C.

a lower selectivity and yield (69% yield, 78% ee, entry 4), whereas no reaction was observed for 2,6-dimethylphenyl boronic acid (**12f**, entry 5). A lower selectivity also was observed with the electron-rich 4-MeO-Ph boronic acid (79% ee, 73% yield, entry 2).

The Rh(I)/DIPHONANE-catalyzed addition was also applied to cyclopentenone **11B** and cycloheptenone **11C** as acceptors. The addition to **11B** resulted in the phenyl adduct **13Ba** with good selectivity and excellent yield (entry 6, 83% ee, 96% yield). Addition to **11C** with both phenylboronic acid (**12a**) and 1-naphthylboronic acid (**12d**) resulted in the corresponding 1,4-adducts with high yield and good stereoselectivity (**13Ca**, entry 7, 98% yield, 86% ee and **13Cd**, entry 8, 96% yield and 95% ee, respectively.)

(15) Hayashi, T.; Takahashi, M.; Takaya, Y.; Ogasawara, M. *J. Am. Chem. Soc.* **2002**, *124*, 5052–5058.

(16) For the assignment of the configuration, see Supporting Information.

(17) Intermolecular Rh-catalyzed 1,2-addition of arylboronic acids to cyclobutanone: (a) Matsuda, T.; Makino, M.; Murakami, M. *Org. Lett.* **2004**, *6*, 1257–1259. (b) Matsuda, T.; Makino, M.; Murakami, M. *Bull. Chem. Soc. Jpn.* **2005**, *78*, 1528–1533. Intramolecular Rh-catalyzed 1,2-addition to ketones: (c) Takewasa, A.; Yamoguchi, K.; Ohmura, T.; Yamamoto, Y.; Miyaura, N. *Synlett* **2002**, 1733–1735. (d) Miura, T.; Shimada, M.; Murakami, M. *Synlett* **2005**, 667–669. (e) Shintani, R.; Okamoto, K.; Otomaru, Y.; Ueyama, K.; Hayashi, T. *J. Am. Chem. Soc.* **2005**, *127*, 54–55. (f) Matsuda, T.; Makino, M.; Murakami, M. *Angew. Chem., Int. Ed.* **2005**, *44*, 4608–4611. Rh-catalyzed trimethylphenylstannane addition to cyclohexanone: (g) Oi, S.; Moro, M.; Fukuhara, H.; Kawanishi, T.; Inoue, Y. *Tetrahedron* **2003**, *59*, 4351–4361.

No reactivity was observed in the addition of **12a** to coumarin **11D** (entry 9).<sup>3q</sup> Although the catalyst showed good reactivity in the addition of **12a** to the linear enone **11E** (92% yield, entry 10), the enantioselectivity dropped remarkably (31% ee). Noteworthy is the fact that 1,2-addition was only observed in minor amounts (<3%) in the case of **13Ad** and **13Ab**.

In conclusion, the Rh(I) complex derived from the new bisdiphenylphosphine DIPHONANE catalyses the asymmetric 1,4-addition of boronic acids to enones with ee's up to 95% ee. The intermediate **2** should allow elaboration of a broader range of 2,5-norbornane bisphosphines, both *C*<sub>2</sub>- and *C*<sub>1</sub>-symmetric.

**Acknowledgment.** The authors gratefully acknowledge financial support by Ghent University. K.V. is a Research Assistant of the Research Foundation-Flanders (F.W.O.-Vlaanderen).

**Supporting Information Available:** Experimental procedures and characterization of compounds **2–6**, **14Aa** and its epimer **15Aa**, and **13Cd**. X-ray crystal structure of (±)-**3** and (1*S*,2*S*,4*S*,5*S*)-**5** in CIF format. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL0522788